ArticleFrontiers in immunology2025
Single-cell transcriptomics reveals a novel mechanism of RDH16 regulating immune infiltration in hepatocellular carcinoma.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hepatocellular carcinoma (HCC) exhibits pronounced intratumoral heterogeneity and a complex immune microenvironment, which together limit therapeutic efficacy. Identifying actionable biomarkers and mechanisms of immune modulation remains critical for improving patient outcomes. Method: We integrated single-cell RNA sequencing data with bulk transcriptomic datasets to comprehensively characterize tumor cell heterogeneity and immune landscape features in HCC. Associations between RDH16 expression and clinicopathological characteristics were evaluated, and in vitro functional assays were conducted. Mendelian randomization analyses were performed to assess causal relationships. Results: RDH16 expression was significantly reduced in HCC tissues compared with non-tumor liver tissues and was associated with vascular invasion, elevated alpha-fetoprotein levels, poor tumor differentiation, and advanced T stage. Higher RDH16 expression was consistently associated with improved overall prognosis. Functional assays indicated that RDH16 did not directly affect tumor cell proliferation, migration, or invasion. Notably, RDH16 expression was inversely correlated with infiltration of CD163⁺ M2 macrophages, suggesting a potential immunomodulatory role in the tumor microenvironment. Mendelian randomization analyses further supported a protective effect of higher RDH16 expression against HCC risk. Discussion: These findings identify RDH16 as an immune-modulating biomarker in HCC, highlighting its potential role in shaping the tumor immune microenvironment and suggesting new avenues for personalized immunotherapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.